Navigation Links
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Date:11/29/2007

ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)announced today that the Circulatory System Devices Advisory Panel to the U.S. Food and Drug Administration (FDA) recommended approval for the XIENCE(TM) V Everolimus Eluting Coronary Stent System. XIENCE V is a next-generation drug eluting stent intended for use in the treatment of coronary artery disease.

The FDA advisory committee voted to recommend the XIENCE V stent system for approval with conditions related to post-marketing study requirements and language related to dual antiplatelet therapy. The FDA is not required to, but usually follows the recommendations of its advisory committees.

"The clinical and angiographic benefits of the XIENCE V stent compared to the most widely used drug eluting stent available in the U.S. have been consistent and significant across the SPIRIT trials," said Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation, New York and principal investigator of the SPIRIT III clinical trial. "The robust body of safety and efficacy data support approval of XIENCE V as an important new technology that will enhance the lives of millions of patients with heart disease."

Abbott filed its Premarket Approval (PMA) submission for XIENCE V with the FDA on June 1, 2007. The PMA for XIENCE V is the first to include data demonstrating superiority of one drug eluting stent over another in the primary endpoint of in-segment late loss in a randomized controlled head-to-head trial with a market leading product.

"The outcome of today's advisory committee meeting is very encouraging," said John M. Capek, Ph.D., executive vice president, Medical Products, Abbott. "We look forward to bringing this important new treatment for coronary artery disease to physicians and patients in the U.S."

XIENCE V was launched in Europe and other international markets in 2006. XIENCE V is currently an investigational
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... In the first study of its kind, Rice University ... circuits that cause cancer cells to become metastatic. The ... allows cancer cells to both migrate and form new ... to new drugs that interfere with the genetic switches ... cells and circulating tumor cells -- two of the ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review that ... loss program ever developed. It promises to provide users the ... no wonder after all that this has become the most ... and workout fat loss program was created by Joel Marion, ... the author of this fat loss system, the method can ...
(Date:10/31/2014)... With all the preparations families carry out ... may overlook one critical area – the potential for ... performance and even behavior. Typical children’s vision screenings at ... vision problems, and to address this challenge, Dr. Rosenak’s ... The Awesome Eyes Student Vision Program. , The ...
(Date:10/31/2014)... FRIDAY, Oct. 31, 2014 (HealthDay News) -- Sleep apnea may ... as where you parked your car or left your house ... with severe sleep apnea showed that this ability -- called ... eye movement (REM) sleep, even when other stages of sleep ... during which dreams typically occur. "We,ve shown for the ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
Breaking Medicine News(10 mins):Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2
... the leading cause of disability among adults. As the population ... // and public health toll of this chronic, crippling joint ... early diagnosis, moderate exercise is one of the most effective ... OA of the knee and hip. , ...
... high fat and sugar induces abnormalities in immune systems, which ... liver, according to a study of mice // conducted by ... published in the Oct. issue of the journal Hepatology, found ... more weight, but also developed fatty livers and increased levels ...
... cause of mortality in patients with muscular dystrophy and ... and approximately 70 % of those with Becker muscular ... muscular dystrophy caused by defects in a gene called ... heart failure and premature death. , ,Cardiac symptoms ...
... Stony Brook University's School of Dental Medicine have developed ... and confections and will not promote cavity formation in ... technology, which has been named CaviStat(R), is more effective ... tooth decay. This conclusion was arrived at after testing ...
... of bilateral muscle weakness with areflexia provoked by ... Cataplexy is diagnosed based on clinical interview. Two ... their usefulness has been limited because of length ... ,Used effectively even these screening tests require the ...
... studies that suggested that radiation treatment for prostate cancer ... suppress hormones. // , ,Researchers at Johns Hopkins ... that hormone therapy will not diminish the value of ... and remains undiagnosed and can present late when the ...
Cached Medicine News:Health News:Exercise Can Strenghten Knee Cartilage 2Health News:Hormone Treatment Before Radiation for Prostate Cancer 2
(Date:10/31/2014)... NEW YORK , Oct. 31, 2014  Grammy ... performance to a high-profile audience of philanthropists, athletes, actors, ... Foundation Gala on Wednesday, November 19 at the Mandarin ... . This year,s fundraising event will honor six individuals ... The Orthopaedic Foundation will bestow its highest honor, ...
(Date:10/31/2014)... , Oct. 31, 2014  Australian biopharmaceutical company Specialised ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will ... patients with metastatic pancreatic cancer from 1 November. ... cancer is the 5 th most common cause ... all cancer deaths, with the lowest 5-year survival of ...
(Date:10/31/2014)... ARBOR, Mich. , Oct. 31, 2014 /PRNewswire/ ... immune modulators to treat autoimmune disease and cancer, ... of novel synthetic RORgamma agonist product candidates will ... Society for Immunotherapy of Cancer (SITC) being held ... & Convention Center, National Harbor, MD.  The poster, ...
Breaking Medicine Technology:10th Anniversary Orthopaedic Foundation Gala Set For Success 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2
... (NYSE: BSX ) today announced financial results for the ... for net sales and earnings per share (EPS) for the ... highlights (Sales growth rates are constant currency): , ... EPS of $0.19, both within the Company,s guidance ranges ...
... NEW ORLEANS, Oct. 19 NCPA 111th Annual Convention ... in targeted pharmacy-based patient care services, has announced the ... National Community Pharmacists Association,s annual convention, MirixaEdge enables pharmacists ... of their patients regardless of health plan, employer, or ...
Cached Medicine Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 27Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 28Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 29Mirixa Corporation Announces MirixaEdge(SM) 2
RABIT (Rapid Automated Bacterial Impedance Technique) has been developed by Don Whitley Scientific over several years with the aid of leading product and computer design consultants....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
Intended for the quantitative determination of albumin in serum or plasma. Reaction: Endpoint. Wavelength: 628 nm. Linearity: 8 g/dl (80 g/l). Ready to use liquid reagent....
Medicine Products: